| scholarly article | Q13442814 |
| P2093 | author name string | Swati Nagar | |
| Ken Korzekwa | |||
| Min Ye | |||
| P2860 | cites work | Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. | Q30583202 |
| Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data | Q30697908 | ||
| Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes | Q30936725 | ||
| Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches | Q30984976 | ||
| Pharmacokinetics of haloperidol: an update | Q33813315 | ||
| Pharmacokinetics and bioavailability of midazolam in man | Q34247690 | ||
| Evaluation of hepatic clearance prediction using in vitro data: emphasis on fraction unbound in plasma and drug ionisation using a database of 107 drugs | Q34304674 | ||
| Pharmacokinetics of chlorpromazine and key metabolites | Q34339444 | ||
| Clinical pharmacokinetics of ketoprofen after single intravenous administration as a bolus or infusion | Q69018946 | ||
| Pharmacokinetics of haloperidol in psychotic patients | Q70342842 | ||
| Physiological Disposition of Fenoprofen in Man II: Plasma and Urine Pharmacokinetics after Oral and Intravenous Administration | Q70398299 | ||
| Physiological disposition of fenoprofen in man. 3. Metabolism and protein binding of fenoprofen | Q70507633 | ||
| A study of the effect of aspirin on the pharmacokinetics of oral and intravenous diclofenac sodium | Q71397270 | ||
| Propafenone disposition kinetics in cardiac arrhythmia | Q71424712 | ||
| Absolute bioavailability of oral immediate and slow release fluphenazine in healthy volunteers | Q71765916 | ||
| Bioavailability of intramuscularly administered tenoxicam | Q72553380 | ||
| Involvement of the rat gut epithelial and muscular layer, and microflora in chiral inversion and acyl-glucuronidation of R-fenoprofen | Q73567796 | ||
| Extrahepatic first-pass metabolism of nifedipine in the rat | Q73616539 | ||
| Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved, and sandwich-cultured hepatocytes | Q78519830 | ||
| Impact of pH on plasma protein binding in equilibrium dialysis | Q80885071 | ||
| PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance | Q84032967 | ||
| Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view | Q84596996 | ||
| Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin | Q35846898 | ||
| Kinetic determinants of hepatic clearance: plasma protein binding and hepatic uptake | Q36985063 | ||
| Modelling and PBPK simulation in drug discovery | Q37413064 | ||
| Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science | Q37790383 | ||
| Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport | Q39578741 | ||
| Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone | Q39930679 | ||
| Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods | Q39978176 | ||
| Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. | Q40647286 | ||
| Physiological parameter values for physiologically based pharmacokinetic models | Q41556435 | ||
| Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man | Q41605631 | ||
| Pharmacokinetics of isoxicam following intravenous, intramuscular, oral and rectal administration in healthy volunteers | Q42017749 | ||
| Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration | Q42532060 | ||
| Pharmacokinetics of felodipine in patients with liver disease | Q42646696 | ||
| Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine | Q43229081 | ||
| The corrected traditional equations for calculation of hepatic clearance that account for the difference in drug ionization in extracellular and intracellular tissue water and the corresponding corrected PBPK equation | Q43629131 | ||
| Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. | Q43740204 | ||
| Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates | Q43955928 | ||
| Commentary: a physiological approach to hepatic drug clearance | Q43996648 | ||
| The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. | Q44217911 | ||
| Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance | Q44804450 | ||
| Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance | Q45001535 | ||
| Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling | Q45046738 | ||
| In vitro-in vivo extrapolation of clearance: modeling hepatic metabolic clearance of highly bound drugs and comparative assessment with existing calculation methods. | Q45175962 | ||
| Nonlinear pharmacokinetics of propafenone in rats and humans: application of a substrate depletion assay using hepatocytes for assessment of nonlinearity | Q45295857 | ||
| Microsome composition-based model as a mechanistic tool to predict nonspecific binding of drugs in liver microsomes | Q45730075 | ||
| Consistency of the novel equations for determination of hepatic clearance and drug time course in liver that account for the difference in drug ionization in extracellular and intracellular tissue water. | Q45957658 | ||
| Functional involvement of rat organic anion transporter 2 (Slc22a7) in the hepatic uptake of the nonsteroidal anti-inflammatory drug ketoprofen | Q46495844 | ||
| Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions | Q48567088 | ||
| Quantitative structure-pharmacokinetics relationships: I. Development of a whole-body physiologically based model to characterize changes in pharmacokinetics across a homologous series of barbiturates in the rat. | Q48685645 | ||
| EEG profile of intravenous zolpidem in healthy volunteers | Q48852678 | ||
| Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds. | Q50785453 | ||
| Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. | Q51030961 | ||
| PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. | Q51572353 | ||
| Pharmacokinetic Comparison of Sublingual Lorazepam with Intravenous, Intramuscular, and Oral Lorazepam | Q51652169 | ||
| Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. | Q51975107 | ||
| Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. | Q52048723 | ||
| A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. | Q52082136 | ||
| Pharmacokinetic profile of diazepam in man following single intravenous and oral and chronic oral administrations. | Q52727393 | ||
| Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. | Q53024733 | ||
| Pharmacokinetics and pharmacodynamics as well as metabolism following orally and intravenously administered C14-glipizide, a new antidiabetic | Q53739870 | ||
| Pharmacokinetic and pharmacodynamic studies of felodipine in healthy subjects after various single, oral and intravenous doses. | Q54407139 | ||
| Partition coefficients and their uses | Q55954394 | ||
| Prazosin, pharmacokinetics and concentration effect | Q66959788 | ||
| Pharmacokinetics and absolute bioavailability of ibuprofen after oral administration of ibuprofen lysine in man | Q67285537 | ||
| Bioavailability and pharmacokinetics of oxazepam | Q67979397 | ||
| Clinical pharmacokinetics of clozapine in chronic schizophrenic patients | Q67989786 | ||
| Pharmacokinetics of various single intravenous and oral doses of omeprazole | Q68624191 | ||
| P433 | issue | 3 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 123-141 | |
| P577 | publication date | 2015-11-03 | |
| P1433 | published in | Biopharmaceutics and Drug Disposition | Q15766879 |
| P1476 | title | A physiologically based pharmacokinetic model to predict the pharmacokinetics of highly protein-bound drugs and the impact of errors in plasma protein binding | |
| P478 | volume | 37 |
| Q46268054 | Integration of a plasma protein binding factor to the Chemical-Specific Adjustment Factor (CSAF) for facilitating the estimation of uncertainties in interspecies extrapolations when deriving health-based exposure limits for active pharmaceutical ing |
| Q48113384 | On the Nature of Physiologically-Based Pharmacokinetic Models -A Priori or A Posteriori? Mechanistic or Empirical? |
| Q90241255 | Relevance of In Vitro Metabolism Models to PET Radiotracer Development: Prediction of In Vivo Clearance in Rats from Microsomal Stability Data |
| Q92400500 | Successful Prediction of Human Pharmacokinetics by Improving Calculation Processes of Physiologically Based Pharmacokinetic Approach |
Search more.